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Foreword 
The pressurized metered ose inhaler (pMDI) remains the 
most commonly prescribed device for the delivery of 
inhaled asthma medications (1,2). The reasons for this 
include: a proven record of delivering drug safely and 
effectively to the lung, ability to deliver a wide range of 
drugs, global availability and relatively low cost (1,2). 
Furthermore, patients who are experienced users of the 
pMDI are comfortable with many features of the device, 
including, for example, its ease of use and small size. 
Although some patients have difficulty using an pMDI this 
can be overcome by the addition of a spacer, which helps to 
reduce the need for co-ordination of inspiration with 
actuation of the inhaler. A spacer device also reduces the 
potential for local side-effects resulting from oropharyngeal 
deposition of a high velocity corticosteroid aerosol spray (3). 
Traditionally, pMDIs have been formulated using the 
chlorofluorocarbon (CFC)propellants 11 and 12. However, 
due to environmental legislation triggered by the Montreal 
protocol some years ago (4), the pharmaceutical industry 
made a commitment o replace CFCs with alternative 
propellants that have less impact on the ozone layer. This 
was despite the fact that, at the time the Montreal protocol 
was ratified, CFC medicinal aerosols contributed to less 
than 1% of overall CFC emissions worldwide (5). 
Glaxo Wellcome has developed salbutamol and flutica- 
sone propionate pMDIs containing the non-CFC propel- 
lant, hydrofluoroalkane (HFA) 134a. The overall objective 
of this research programme is to provide physicians and 
patients with non-CFC products that have similar proper- 
ties to the existing CFC products with respect to 
pharmaceutical, pharmacological and clinical performance. 
The ultimate aim is to ensure a relatively seamless transition 
from CFC to non-CFC pMDIs without any change in 
therapeutic ratio or dosage regimen. 
Pharmaceutical nd pharmacokinetic evaluations have 
shown comparability at microgram equivalent doses 
between the CFC and HFA 134a pMDIs for both 
fluticasone propionate with or without a spacer (6,7) and 
salbutamol (data on file). However, the ultimate test is to 
demonstrate clinical equivalence with respect to efficacy 
and safety in patients with asthma. 
The Glaxo Wellcome clinical programme for the 
registration of the fluticasone propionate HFA 134a pMDI 
was designed to determine clinical equivalence between the 
CFC and HFA 134a products. Double blind, randomized, 
parallel-group or cross-over studies were conducted for 
each strength of fluticasone propionate (50/tg, 125#g and 
250#g) to compare the CFC and HFA 134a pMDIs. The 
results of the studies for the 125/~g and 250 pg strengths are 
presented in this supplement. The clinical equivalence 
programme did not rely on extrapolation of data from 
one strength of fluticasone propionate to another. 
The programme of studies included a wide variety of 
patients with different asthma severities treated with the 
appropriate strength of drug. Patient entry criteria were 
carefully controlled to avoid making comparisons between 
treatments at the plateau of the dose-response curve. Thus, 
patients were only randomized to treatment if, during a 
carefully monitored run-in period, there was clear evidence 
of room for improvement. This was confirmed by the 
following: a mean morning peak expiratory flow (PEF) of 
_<90% of the maximum PEF after inhalation of salbutamol 
400 or 800 pg; demonstrable r versibility of PEF or forced 
expiratory volume in 1 sec (FEV 0 of _>15%; a requirement 
for as-required flTagonist; and asthma symptomatology. 
Using these criteria, randomization to the two treatment 
groups produced improvements in lung function which 
were below the maximum achievable, thereby confirming 
that comparisons were made on the steep part of the dose- 
response curve. Ideally, such studies hould include a dose- 
response comparison. However, practically this is difficult 
and the fluticasone propionate studies published in this 
supplement represent a balance between clinical reality and 
optimal study design. 
Each study was conducted in accordance with the 
Committee for Proprietary Medicinal Products (CPMP) 
guidelines for clinical equivalence t sting between CFC and 
HFA 134a products (8). Furthermore, the study designs 
were of appropriate duration and captured suitable 
markers of efficacy and safety. For example, fluticasone 
propionate, 1000 pg day-  i was studied for a period of up to 
l year using the 250pg pMDI. The primary marker of 
efficacy, dairy card morning PEF, was complemented by 
secondary markers which included symptom scores, clinic 
lung function and as-required fl2-agonist use. Appropriate 
markers of safety were also included, such as measurement 
of serum cortisol levels and incidence of both routine 
adverse events and pharmacologically predictable vents 
over a period of up to I year. All the'fluticasone propionate 
studies were statistically robust. Clinical equivalence 
between the HFA 134a and CFC pMDIs was established 
if the 90% confidence intervals for the treatment difference 
of mean morning PEF were within _+lSImin - I .  This 
necessitated the evaluation of a relatively large number of 
patients (for example, > 300 patients in each of the parallel- 
group studies). 
Equivalence between the salbutamol HFA 134a and CFC 
pMDIs has been demonstrated in single-dose challenge 
studies in adults and children (9,10). The HFA 134a 
salbutamol pMDI has also been evaluated in a clinical 
context in two further studies, the results of which 
are presented in this supplement. One study evaluated 
as-required salbutamol and therefore represented 
typical clinical use in accordance with international 
recommended guidelines. The second study evaluated 
regular use of salbutamol, which although not advocated 
in asthma treatment guidelines, continues to be used by 
many patients. 
In conclusion, the clinical data presented in this 
supplement demonstrate that the salbutamol and flutica- 
sone propionate HFA 134a pMDI products are equivalent 
to their CFC counterparts at microgram equivalent doses 
0954-6111/00/0B000S1+02 $35.00/0 © 2000 HARCOURT PUBLISHERS LTD 
$2 G. BRatrNSa~tN 
with respect o clinical efficacy and safety. These findings 
should facilitate a more seamless transition from CFC.to 
HFA 134a pMDIs. 
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